D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Shingrix’s strong showing was mainly the result of a large order from a U.S. retail pharmacy chain, GSK chief commercial officer Luke Miels told investors during a separate call. After the ...

In August 2023, GSK announced data from the ZOSTER-076 phase 4 trial showing that Shingrix demonstrated 100% vaccine efficacy in preventing shingles in Chinese adults aged 50 and over.

GSK expects to start distributing Shingrix by the end of November, but health insurance coverage is not expected to be in place until mid-2018. A two-shot Shingrix immunization costs $280 if not ...

July 24 (Reuters) - GlaxoSmithKline GSK.L beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller ...